Figure 2: Agilent supports and integrates single and multi-omics experiments, simplifying the researcher’s cyclical journey between hypothesis-free discovery and pathway/hypothesis-driven validation
Learn more at Pathways to Insight—Integrated Biology at Agilent.
The integration of genomic, transcriptomic, proteomic and metabolomics is advancing rapidly, providing new insights into the study of biological response mechanisms. Recent published examples of pathway-driven multi-omics research show how these types of analyses can yield valuable information about drug responses, drug resistance, diagnostic markers, and fundamental disease/toxicity pathways.
The urgent need for a more mechanistic understanding of the ways in which chemicals modulate biological pathways is required in order to identify and better assess safety issues relating to a wide range of substances developed by the pharmaceutical, chemical, agricultural, biological and cosmetic industries. Omics technologies provide a valuable opportunity to refine existing methods and provide the basis for integrated testing strategies.
Integrated testing strategies include multi-omics data and modeling, using both in vivo and cell-based assays. These strategies are gaining traction as a viable approach in the development of a pathway-based mechanistic view of biochemically induced bioactivity.
Complete Omics Solution
Agilent’s pathway-based, multi-omics technologies work together to form a complete integrated biology platform. These technologies feature state-of-the-art instruments, reagents and software for genomics, proteomics, metabolomics, transcriptomics, and bioinformatics. For more information on Agilent’s Integrated Biology portfolio, please visit: Agilent Integrated Biology.